Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained

Related Keywords

Sweden ,Stockholm ,Belgium ,Jordan ,Leuven ,Region Flamande ,Stephanie Kenney ,Hansa Biopharma ,Prnewswire Hansa Biopharma ,Dirk Kuypers ,Klaus Sindahl ,Department Of Nephrology ,University Hospitals Leuven ,European Union ,European Medicines Agency Ema Priority ,Renal Transplantation Program ,Vp Global Corporate Affairs ,European Medicines Agency ,Nasdaq Stockholm ,Human Leukocyte Antigens ,Product Characteristics ,End Stage Renal Disease ,Dial Transplant ,Englj Med ,Hansa ,Iopharma ,Nnounces ,Positive ,Reimbursement ,Decision ,Defirix ,Mlifidase ,Desensitization ,Treatment ,Ighly ,Desensitized ,Patients ,Kidney ,Transplantation ,